Table 3.
NAFLD status overtime | Baseline obesity | BMI change | ||||||
---|---|---|---|---|---|---|---|---|
|
|
|||||||
Nonobese group (n=2,000) | Obese group (n=726) | Decreased BMI (n=874) | Increased BMI (n=1,852) | |||||
|
|
|
|
|||||
HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
No NAFLD | 1 (Reference) | |||||||
Resolved NAFLD | 1.87 (0.53–6.54) | 0.330 | 0.493 (0.06–4.24) | 0.519 | 1.38 (0.44–4.35) | 0.579 | 1.75 (0.42–7.36) | 0.412 |
Incident NAFLD | 2.51 (1.27–4.95) | 0.008 | 1.73 (0.57–5.27) | 0.333 | 2.68 (1.08–6.65) | 0.034 | 2.41 (1.12–5.20) | 0.025 |
Persistent NAFLD | 4.78 (2.45–9.35) | <0.001 | 2.71 (1.04–7.09) | 0.042 | 2.18 (1.03–4.62) | 0.042 | 5.51 (2.55–11.91) | <0.001 |
Adjusted for age, sex, fasting glucose, body mass index (BMI), waist circumference, and baseline alanine transaminase levels.
HR, hazard ratio; CI, confidence interval; NAFLD, nonalcoholic fatty liver disease.